Neuroleptic malignant syndrome

Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.

Saved in:
Bibliographic Details
Main Authors: Moscovich,Mariana, Nóvak,Felipe T.M., Fernandes,Artur F., Bruch,Tatiana, Tomelin,Tabita, Nóvak,Edison M., Munhoz,Renato P., Teive,Hélio A.G.
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000600005
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2011000600005
record_format ojs
spelling oai:scielo:S0004-282X20110006000052011-10-27Neuroleptic malignant syndromeMoscovich,MarianaNóvak,Felipe T.M.Fernandes,Artur F.Bruch,TatianaTomelin,TabitaNóvak,Edison M.Munhoz,Renato P.Teive,Hélio A.G. atypical antipsychotics typical antipsychotics neuroleptic malignant syndrome Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.69 n.5 20112011-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000600005en10.1590/S0004-282X2011000600005
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Moscovich,Mariana
Nóvak,Felipe T.M.
Fernandes,Artur F.
Bruch,Tatiana
Tomelin,Tabita
Nóvak,Edison M.
Munhoz,Renato P.
Teive,Hélio A.G.
spellingShingle Moscovich,Mariana
Nóvak,Felipe T.M.
Fernandes,Artur F.
Bruch,Tatiana
Tomelin,Tabita
Nóvak,Edison M.
Munhoz,Renato P.
Teive,Hélio A.G.
Neuroleptic malignant syndrome
author_facet Moscovich,Mariana
Nóvak,Felipe T.M.
Fernandes,Artur F.
Bruch,Tatiana
Tomelin,Tabita
Nóvak,Edison M.
Munhoz,Renato P.
Teive,Hélio A.G.
author_sort Moscovich,Mariana
title Neuroleptic malignant syndrome
title_short Neuroleptic malignant syndrome
title_full Neuroleptic malignant syndrome
title_fullStr Neuroleptic malignant syndrome
title_full_unstemmed Neuroleptic malignant syndrome
title_sort neuroleptic malignant syndrome
description Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000600005
work_keys_str_mv AT moscovichmariana neurolepticmalignantsyndrome
AT novakfelipetm neurolepticmalignantsyndrome
AT fernandesarturf neurolepticmalignantsyndrome
AT bruchtatiana neurolepticmalignantsyndrome
AT tomelintabita neurolepticmalignantsyndrome
AT novakedisonm neurolepticmalignantsyndrome
AT munhozrenatop neurolepticmalignantsyndrome
AT teivehelioag neurolepticmalignantsyndrome
_version_ 1756374526457806848